DCTH

Purpura John

Known title: Chief Operating OfficerCIK: 0001485555

Purpura John's purchase track record

How the stock did after each of Purpura John's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
3
of 3 since April 11, 2022
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-41.1%
3 months: -4.0%
Beat the S&P 500
33%
median -38.0% vs. index
PurchaseStockAmount3 months6 months
10/13/2023DCTH$50K+15.3%+43.1%
5/16/2022DCTH$15K-4.0%-41.1%
4/11/2022DCTH$33K-37.8%-56.2%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

Veracyte stock moves; DCTH shows no related news. Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.

this person other insiders at DCTH

Transaction History

DCTH▲ Buy$50K
DCTH▲ Buy$15K
DCTH▲ Buy$33K

We use analytics to understand how market-wall is used. No personal data is sold.